公开(公告)号：EP4387647A2

公开(公告)日：2024-06-26

申请号：EP22858988.3

申请日：2022-08-15

申请人： Acceleron Pharma Inc.

发明人： KUMAR, Ravindra

IPC分类号： A61K38/17 ,  C07K14/71 ,  A61P13/12

CPC分类号： A61K38/1796 ,  A61K38/05 ,  A61K38/556 ,  A61K38/13 ,  A61K38/2006 ,  A61K38/1774 ,  A61K38/1793 ,  A61K38/08 ,  A61K35/28 ,  C07K2319/3020130101 ,  A61K31/4178 ,  A61K31/55

公开(公告)号：EP3107559B1

公开(公告)日：2018-07-11

申请号：EP15706006.2

申请日：2015-02-20

申请人： Merck Patent GmbH

发明人： LADEL, Christoph H. ,  GUEHRING, Hans

IPC分类号： A61K38/18 ,  A61P19/02

CPC分类号： A61K38/1825 ,  A61K9/0019 ,  A61K31/196 ,  A61K38/16 ,  A61K38/2006 ,  A61K45/06

摘要： The present invention provides a new dosing regimen for administration of FGF-18 in the treatment of a cartilage disorder, such as osteoarthritis or cartilage injury. Specifically provided is a preferred treatment scheme comprising administrations every 3 weeks, 4 weeks or 5 weeks of an FGF-18 compound per treatment cycle. The new dosing regimen can include the co-adminsitration of an anti-inflammatory drug.

公开(公告)号：EP2429585B1

公开(公告)日：2018-04-18

申请号：EP10775661.1

申请日：2010-05-17

申请人： IRX Therapeutics, Inc.

发明人： HADDEN, John W. ,  SIGNORELLI, Kathy ,  EGAN, James ,  NAYLOR, Paul

IPC分类号： A61K45/00 ,  A61K38/21

CPC分类号： A61K39/39 ,  A61K38/164 ,  A61K38/177 ,  A61K38/191 ,  A61K38/193 ,  A61K38/2006 ,  A61K38/2013 ,  A61K38/204 ,  A61K38/2053 ,  A61K38/208 ,  A61K38/217 ,  A61K39/0011 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/55522 ,  A61K2039/55561 ,  A61K2039/55588 ,  A61K2039/6081 ,  A61K2300/00

摘要： A composition for treating cancer, including synergistic amounts of a primary cell-derived biologic having the cytokines IL-1, IL-2, IL-6, IL-8, TNF-α, and IFN-γ, and a cancer vaccine having at least one antigen. A composition comprising synergistic amounts of the primary cell-derived biologic in combination with at least one adjuvant. A method of treating cancer by administering the composition. A method of reversing immune suppression and gaining immunity to cancer. A method of producing an immune response to an exogenous antigen. A method of enhancing an immune response in a patient by administering the primary cell-derived biologic in combination with at least one adjuvant, and enhancing the immune response of the patient by a synergistic interaction of the primary cell-derived biologic and the adjuvant. A method of increasing function of an immune system.

公开(公告)号：EP3288536A1

公开(公告)日：2018-03-07

申请号：EP16722558.0

申请日：2016-04-27

申请人： Swedish Orphan Biovitrum AB (publ)

发明人： FLORIN-ROBERTSSON, Ebba ,  FRANSSON, Jonas ,  MOORE, Barry D.

IPC分类号： A61K9/00 ,  A61K38/20 ,  A61P27/02

CPC分类号： A61K38/2006 ,  A61K9/0048 ,  A61K47/02 ,  A61K47/12 ,  A61K47/183 ,  A61K47/20 ,  A61K47/22 ,  A61K47/26 ,  A61P27/02 ,  A61P27/04 ,  A61P27/14 ,  A61K2300/00

摘要： The present invention relates to compositions comprising anakinra, buffer, and optionally at least one osmolyte and optionally further excipients. Further, the present invention relates to use of said compositions for treatment of for example ophthalmic disorders.

公开(公告)号：EP3242680A2

公开(公告)日：2017-11-15

申请号：EP16703357.0

申请日：2016-01-07

申请人： Linnane Pharma AB

发明人： SVANBORG, Catharina ,  AMBITES, Ines

IPC分类号： A61K38/17 ,  A61K31/00 ,  G01N33/48 ,  A61P13/02

CPC分类号： A61K38/2006 ,  A61K31/381 ,  A61K38/17 ,  A61P13/02 ,  C12Q1/68 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Y304/24023 ,  G01N33/573 ,  G01N33/6869 ,  G01N33/6893 ,  G01N2333/545 ,  G01N2333/96494 ,  G01N2800/348 ,  G01N2800/50

摘要： A method for treating cystitis, in particular acute cystitis, comprising administering to a patient in need thereof, an effective amount of a reagent selected from the group consisting of IL-1β inhibitors and MMP inhibitors, or proteins selected from ASC or NLRP-3. Diagnostic methods are also described and claimed.

公开(公告)号：EP3214442A1

公开(公告)日：2017-09-06

申请号：EP17158409.7

申请日：2011-10-25

申请人： F. Hoffmann-La Roche AG

发明人： GONZALES, Lino ,  OUYANG, Wenjun ,  PAPPU, Rajita ,  RAMIREZ-CARROZI, Vladimir

IPC分类号： G01N33/53 ,  C07K16/28 ,  A01K67/027 ,  A61K38/20 ,  A61P37/02

CPC分类号： C07K16/2866 ,  A61K38/1793 ,  A61K38/191 ,  A61K38/2006 ,  C07K14/54 ,  C07K2317/76 ,  A61K2300/00

摘要： The present invention provides methods and means to reduce gastrointestinal inflammation. In particular, the invention provides methods and means to treat inflammatory bowel disease (IBD) and related conditions. The invention further provides methods and means to treat psoriasis. The invention further provides methods and means to treat asthma.

摘要翻译： 本发明提供了减少胃肠炎症的方法和手段。 具体而言，本发明提供了治疗炎症性肠病（IBD）和相关病症的方法和手段。 本发明进一步提供了治疗牛皮癣的方法和手段。 本发明进一步提供了治疗哮喘的方法和手段。

公开(公告)号：EP2755679B1

公开(公告)日：2017-08-02

申请号：EP12831033.1

申请日：2012-09-12

申请人： Immunotope, Inc.

发明人： PHILIP, Ramila

IPC分类号： A61K39/00 ,  A61K39/38

CPC分类号： A61K39/0011 ,  A61K38/191 ,  A61K38/193 ,  A61K38/2006 ,  A61K38/2013 ,  A61K38/2046 ,  A61K38/208 ,  A61K38/2086 ,  A61K2039/55566 ,  A61K2039/572 ,  C07K7/06 ,  C07K14/4748 ,  C07K14/70539

摘要： The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of cancer, especially carcinomas, such as pancreatic carcinoma. The invention discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against pancreatic and other cancers.

公开(公告)号：EP3054978A4

公开(公告)日：2017-05-10

申请号：EP14852319

申请日：2014-10-08

申请人： UNIV GEORGIA STATE RES FOUND INC

发明人： GEWIRTZ ANDREW T ,  ZHANG BENYUE

IPC分类号： A61K38/20 ,  A61K45/00 ,  A61P31/12

CPC分类号： A61K38/20 ,  A61K9/0019 ,  A61K38/2006 ,  A61K47/48284 ,  A61K47/48423 ,  A61K47/643 ,  A61K47/6813 ,  A61K2300/00

摘要： The present invention is directed to compositions including the cytokines IL-18 and IL-22 or biologically active fragments or variants thereof. In some embodiments, the compositions further include a pharmaceutically acceptable carrier. The compositions can further include other interleukins such as IL-1β, and IL 1β can be used as a combination therapy with either IL-18 or IL-22 or biologically active fragments or variants thereof.

摘要翻译： 本发明涉及包含细胞因子IL-18和IL-22或其生物活性片段或变体的组合物。 在一些实施方案中，组合物还包含药学上可接受的载体。 组合物可以进一步包含其他白细胞介素例如IL-1β，IL1β可以用作与IL-18或IL-22或其生物活性片段或变体的组合疗法。

公开(公告)号：EP3119417A1

公开(公告)日：2017-01-25

申请号：EP15707076.4

申请日：2015-02-20

申请人： Merck Patent GmbH

发明人： LADEL, Christoph H. ,  GUEHRING, Hans

IPC分类号： A61K38/18 ,  A61P19/02

CPC分类号： A61K38/1825 ,  A61K9/0019 ,  A61K31/196 ,  A61K38/16 ,  A61K38/2006 ,  A61K45/06

摘要： The present invention provides a new dosing regimen for administration of FGF-18 in the treatment of a cartilage disorder, such as osteoarthritis or cartilage injury. Specifically provided is a preferred treatment scheme comprising administrations every 3 weeks, 4 weeks or 5 weeks of an FGF-18 compound per treatment cycle. The new dosing regimen can include the co-adminsitration of an anti-inflammatory drug.

摘要翻译： 本发明提供了用于施用FGF18在治疗软骨疾病如骨关节炎或软骨损伤中的新的给药方案。 具体提供的是优选的治疗方案，其包括每治疗周期每2周施用FGF-18化合物。 新的给药方案可以包括抗炎药物的共同给药。

公开(公告)号：EP3054982A1

公开(公告)日：2016-08-17

申请号：EP14784022.7

申请日：2014-10-07

申请人： Ascendis Pharma Osteoarthritis Division A/S

发明人： RAU, Harald ,  ZETTLER, Joachim ,  HERSEL, Ulrich ,  KALUZA, Nora ,  KRUSCH, Mathias ,  VOIGT, Tobias

IPC分类号： A61K47/48 ,  A61P19/02

CPC分类号： A61K38/2006 ,  A61K47/60 ,  A61K47/6903

摘要： The present invention relates to a hydrogel-linked IL-Ira prodrug or pharmaceutically acceptable salt thereof. It further relates to a pharmaceutical composition comprising said hydrogel-linked IL-Ira prodrug, its use as medicament for the treatment of a IL-1 mediated disease, ways of application of such hydrogel-linked IL-Ira prodrugs or pharmaceutical compositions, and containers comprising the hydrogel-linked IL-Ira prodrugs or pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising said hydrogel-linked IL-Ira prodrug or pharmaceutically acceptable salt thereof.

摘要翻译： 本发明涉及水凝胶连接的IL-Ira前药或其药学上可接受的盐。 本发明还涉及包含所述水凝胶连接的IL-1α前药的药物组合物，其作为用于治疗IL-1介导的疾病的药物的用途，应用这种水凝胶连接的IL-1α前药或药物组合物的方式，以及容器 其包含水凝胶连接的IL-1a前药或其药学上可接受的盐或包含所述水凝胶连接的IL-1a前药或其药学上可接受的盐的药物组合物。